Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.

Published

Journal Article

Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease (FD), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. Symptomatic adults with FD participated in this open-label, 3-month dose-ranging study, followed by a 9-month extension. Three cohorts were enrolled in a stepwise manner, each receiving increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and 12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other clinical endpoints were assessed throughout. Treatment-emergent adverse events (AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female patients presented with classic FD phenotype, in whom renal peritubular capillary Gb3 inclusions were reduced by 84%. Mean estimated glomerular filtration rate was 111 mL/min/1.73 m2 at baseline, remaining stable throughout treatment. Three patients developed treatment-induced IgG ADAs; following 1 year's treatment, all became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate. One patient withdrew from the study following a serious related AE. Pegunigalsidase alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity.

Full Text

Duke Authors

Cited Authors

  • Schiffmann, R; Goker-Alpan, O; Holida, M; Giraldo, P; Barisoni, L; Colvin, RB; Jennette, CJ; Maegawa, G; Boyadjiev, SA; Gonzalez, D; Nicholls, K; Tuffaha, A; Atta, MG; Rup, B; Charney, MR; Paz, A; Szlaifer, M; Alon, S; Brill-Almon, E; Chertkoff, R; Hughes, D

Published Date

  • May 2019

Published In

Volume / Issue

  • 42 / 3

Start / End Page

  • 534 - 544

PubMed ID

  • 30834538

Pubmed Central ID

  • 30834538

Electronic International Standard Serial Number (EISSN)

  • 1573-2665

Digital Object Identifier (DOI)

  • 10.1002/jimd.12080

Language

  • eng

Conference Location

  • United States